<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657266</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH155-0412/II</org_study_id>
    <nct_id>NCT01657266</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification</brief_title>
  <official_title>Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution
      PRO-155 in patients post phacoemulsification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postsurgical inflammation is an inevitable condition after cataract surgery. The use of
      non-steroidal anti-inflammatory drugs is a safe option for treating ocular inflammation.

      This is a phase II randomized double-blind clinical trial. The aim is to compare and to
      evaluate efficacy and safety of two ophthalmic solutions in patients post
      phacoemulsification. Patients will be randomized to receive either PRO-155 or Nevanac for 60
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Cellularity in Anterior Chamber</measure>
    <time_frame>day 30</time_frame>
    <description>Change from Percentage of Cellularity in anterior chamber after 30 days of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flare in Anterior Chamber</measure>
    <time_frame>day 30</time_frame>
    <description>Percentage of Participants with flare in anterior chamber after 30 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Without Ocular Pain</measure>
    <time_frame>day 30</time_frame>
    <description>percentage of patients without pain, would be measured using the Visual Analog Pain Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Aqueous Concentration of Intervention Drug</measure>
    <time_frame>before surgery</time_frame>
    <description>a nurse was instructed to instill five drops of the research product into each patient's eye in the hour before surgery. The concentration of the drug was determined for aqueous humor sample (0.15 mL) with a 30-gauge needle on a TB syringe after completion of the paracentesis. The paracentesis was performed after first incision during the phacoemulsification.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Epithelial Defects Detected With Fluorescein</measure>
    <time_frame>measurements will be made at days 1, 5, 7 and 30</time_frame>
    <description>The percentage of patients presenting epithelial defects with fluorescein staining will be evaluated</description>
  </other_outcome>
  <other_outcome>
    <measure>Epithelial Defects Detected With Green Lissamine</measure>
    <time_frame>measurements will be made at days 1, 5, 7 and 30</time_frame>
    <description>the percentage of patients presenting epithelial defects evaluated with green lysine will be reported</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>day 30</time_frame>
    <description>Change from Baseline in the intraocular pressure after 30 days of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>day 30 and 60</time_frame>
    <description>Change from Baseline in retinal thickness after 30 days of treatment. A third measurement will be done at 60 day after day surgery.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Cataract</condition>
  <condition>Phacoemulsification Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>PRO-155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevanac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-155</intervention_name>
    <description>Pre-medication (before surgery) and maintenance treatment.</description>
    <arm_group_label>PRO-155</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevanac</intervention_name>
    <description>Pre-medication (before surgery) and maintenance treatment.</description>
    <arm_group_label>Nevanac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years who require cataract surgery

          -  Both genders

          -  Provide informed consent

          -  Normal Laboratory results

        Exclusion Criteria:

          -  Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery

          -  Patients with any trans-surgical complication

          -  Patients with a cataract &gt;NC4, C4 or P4 classified with the system LOCS

          -  Patients with any active corneal pathology

          -  Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior
             surgery or NSAIDs 7 days before the surgery (except low-dose aspirin)

          -  Patients with IOP &lt;5 or &gt;21 mmHg

          -  Patients that have ocular pain, cellularity or flare at the moment of selection

          -  Patients with ocular exfoliation, trauma or any inflammatory disease

          -  Patients with diabetic retinopathy that need treatment or uncontrolled diabetes
             mellitus

          -  Patients who are planning cataract surgery of the contralateral eye 14 days after
             surgery of the study eye

          -  Patients with history of hypersensitivity or contraindication for any drug used in the
             study

          -  Patients under anticoagulant treatment

          -  Contact lens users

          -  Pregnant patients, at risk of pregnancy or breastfeeding

          -  Patients without birth control treatment

          -  Patients with any active toxicomania (alcoholism, cigarette, cannabis or others)

          -  Patients who had participated in any clinical trial in the last 90 days

          -  Legal or mentally disabled patients who could not give informed consent

          -  Patients who cannot comply with all study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo M. Baiza-Dur√°n, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734805/pdf/opth-10-233.pdf</url>
    <description>Palacio C, et al. Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population. Clinical Ophthalmology 2016;10:233-237</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <results_first_submitted>June 14, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bromfenac</keyword>
  <keyword>nepafenac</keyword>
  <keyword>cataract</keyword>
  <keyword>phacoemulsification cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The personal data were collected and analyzed according to confidentiality policy.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>160 subjects were recruited, 12 of whom were excluded, 10 because they did not meet the selection criteria and 2 refused to participate. The remaining 148 were randomly assigned to one of the 2 study groups, 73 to bromfenac and 75 to napaphenac.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PRO-155</title>
          <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
        <group group_id="P2">
          <title>Nevanac</title>
          <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mexican patients.</population>
      <group_list>
        <group group_id="B1">
          <title>PRO-155</title>
          <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
        <group group_id="B2">
          <title>Nevanac</title>
          <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="11.1"/>
                    <measurement group_id="B2" value="68.0" spread="9.5"/>
                    <measurement group_id="B3" value="67.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Cellularity in Anterior Chamber</title>
        <description>Change from Percentage of Cellularity in anterior chamber after 30 days of treatment.</description>
        <time_frame>day 30</time_frame>
        <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cellularity in Anterior Chamber</title>
          <description>Change from Percentage of Cellularity in anterior chamber after 30 days of treatment.</description>
          <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>Percentage of Cellularity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Pearson¬¥s Chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flare in Anterior Chamber</title>
        <description>Percentage of Participants with flare in anterior chamber after 30 days of treatment</description>
        <time_frame>day 30</time_frame>
        <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Flare in Anterior Chamber</title>
          <description>Percentage of Participants with flare in anterior chamber after 30 days of treatment</description>
          <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>Percentage of Participants with flare</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Without Ocular Pain</title>
        <description>percentage of patients without pain, would be measured using the Visual Analog Pain Scale</description>
        <time_frame>day 30</time_frame>
        <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Without Ocular Pain</title>
          <description>percentage of patients without pain, would be measured using the Visual Analog Pain Scale</description>
          <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Aqueous Concentration of Intervention Drug</title>
        <description>a nurse was instructed to instill five drops of the research product into each patient's eye in the hour before surgery. The concentration of the drug was determined for aqueous humor sample (0.15 mL) with a 30-gauge needle on a TB syringe after completion of the paracentesis. The paracentesis was performed after first incision during the phacoemulsification.</description>
        <time_frame>before surgery</time_frame>
        <population>We enrolled patients of both sexes (aged &gt;18 years) with a diagnosis of cataract according to the Lens Opacities Classification System III ‚â§ NC4, C4 and, P4 in one eye were eligible for enrollment. Eligible patients must have had a best-corrected visual acuity of 6/60 (20/200) Snellen score.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Aqueous Concentration of Intervention Drug</title>
          <description>a nurse was instructed to instill five drops of the research product into each patient's eye in the hour before surgery. The concentration of the drug was determined for aqueous humor sample (0.15 mL) with a 30-gauge needle on a TB syringe after completion of the paracentesis. The paracentesis was performed after first incision during the phacoemulsification.</description>
          <population>We enrolled patients of both sexes (aged &gt;18 years) with a diagnosis of cataract according to the Lens Opacities Classification System III ‚â§ NC4, C4 and, P4 in one eye were eligible for enrollment. Eligible patients must have had a best-corrected visual acuity of 6/60 (20/200) Snellen score.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.5" spread="152.3"/>
                    <measurement group_id="O2" value="314.4" spread="146.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Epithelial Defects Detected With Fluorescein</title>
        <description>The percentage of patients presenting epithelial defects with fluorescein staining will be evaluated</description>
        <time_frame>measurements will be made at days 1, 5, 7 and 30</time_frame>
        <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Defects Detected With Fluorescein</title>
          <description>The percentage of patients presenting epithelial defects with fluorescein staining will be evaluated</description>
          <population>Mexican patients patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>percentage of patients with defects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Epithelial Defects Detected With Green Lissamine</title>
        <description>the percentage of patients presenting epithelial defects evaluated with green lysine will be reported</description>
        <time_frame>measurements will be made at days 1, 5, 7 and 30</time_frame>
        <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Defects Detected With Green Lissamine</title>
          <description>the percentage of patients presenting epithelial defects evaluated with green lysine will be reported</description>
          <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>percentage of patients with defects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intraocular Pressure</title>
        <description>Change from Baseline in the intraocular pressure after 30 days of treatment</description>
        <time_frame>day 30</time_frame>
        <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure</title>
          <description>Change from Baseline in the intraocular pressure after 30 days of treatment</description>
          <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.07" spread="1.82"/>
                    <measurement group_id="O2" value="14.23" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.66" spread="2.61"/>
                    <measurement group_id="O2" value="15.83" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.13" spread="1.97"/>
                    <measurement group_id="O2" value="14.54" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.81" spread="1.64"/>
                    <measurement group_id="O2" value="13.91" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.10" spread="1.78"/>
                    <measurement group_id="O2" value="13.77" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Retinal Thickness</title>
        <description>Change from Baseline in retinal thickness after 30 days of treatment. A third measurement will be done at 60 day after day surgery.</description>
        <time_frame>day 30 and 60</time_frame>
        <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-155</title>
            <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Thickness</title>
          <description>Change from Baseline in retinal thickness after 30 days of treatment. A third measurement will be done at 60 day after day surgery.</description>
          <population>Mexican patients who underwent cataract surgery in only 1 eye, by phacoemulsification with intraocular lens implantation.</population>
          <units>Œºm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>field A1 day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.24" spread="32.90"/>
                    <measurement group_id="O2" value="250.87" spread="34.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>field A1 day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.06" spread="24.95"/>
                    <measurement group_id="O2" value="264.08" spread="34.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>field A1 day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.06" spread="2.78"/>
                    <measurement group_id="O2" value="260.13" spread="33.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Interval of 30 days of intervention in which adverse events could occur, included in the treatment period (January 2014-2015)</time_frame>
      <desc>During the pharmacological intervention period, in each visit, the principal investigator asked information about adverse events:
Serious or No serious
Severity: mild, moderate, severe
relation with study drug or not</desc>
      <group_list>
        <group group_id="E1">
          <title>PRO-155</title>
          <description>Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
PRO-155: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
        <group group_id="E2">
          <title>Nevanac</title>
          <description>Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
Maintenance therapy: 1 drop 3 times a day for 30 days
Nevanac: Pre-medication (before surgery) and maintenance treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <description>This serious adverse event occurred during the systematic assessment. The event was not related with the pharmacological intervention.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>central retinal artery occlusion</sub_title>
                <description>This serious adverse event occurred during systematic assessment. The adverse event was not related with the pharmacological intervention.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular edema</sub_title>
                <description>This moderate adverse event does not relationship with the study drug. The clinically significant cystoid macular edema occurs after cataract surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Traumatic corneal desepithelization</sub_title>
                <description>This moderate event does not have relationship with the study drug. The patient presented an accidental ocular injure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Posterior Capsular Rupture</sub_title>
                <description>This mild adverse event does not relationship with the study drug. The posterior capsular rupture occurs after cataract surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>viral conjunctivitis</sub_title>
                <description>This severe adverse event does not have relationship with the study drug. This patient had hypothyroidism like concomitant disease, this clinical condition would be able to increase the risk to have an infectious disease.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Inflammatory cells in the corneal endothelium</sub_title>
                <description>This moderate adverse event does not have relationship with the study drug. The presence of inflammatory cells in the corneal endothelium is related to cataract surgery procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>intraocular lens exchange</sub_title>
                <description>This adverse event does not have relationship with the study drug. The reason of intraocular lens exchange was: error in the intraocular lens power calculation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>fall from their own height</sub_title>
                <description>The mild adverse event does not have relationship with the study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.
All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was performed according to the clinical protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leopoldo M Baiza-Duran MD, Clinical trials Director</name_or_title>
      <organization>Laboratorios Sophia S.A. de C.V.</organization>
      <phone>52+ (33) 30 01 42 00</phone>
      <email>leopoldo.baiza@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

